Akademska digitalna zbirka SLovenije - logo
ALL libraries (COBIB.SI union bibliographic/catalogue database)
Full text
  • Current antipsychotics [Elektronski vir]
    "Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, ... psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics ... Our intention was to capture both the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We [prepared] two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume."--Publisher's description
    Type of material - e-book
    Publication and manufacture - Heidelberg ; New York : Springer, ©2012
    Language - english
    ISBN - 978-3-642-25761-2; 3-642-25761-5
    COBISS.SI-ID - 1545485279

    Link(s):

    SpringerLink e-books 2008-2012

    Celotno besedilo dostopno za uporabnike SpringerLink slovenskega konzorcija neprofitnih institucij

    Full text accessible to the users of SpringerLink Slovenian Consortium of Non-Profit Institutions


    DOI

Shelf entry